CY1117964T1 - Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεας - Google Patents
Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεαςInfo
- Publication number
- CY1117964T1 CY1117964T1 CY20161100858T CY161100858T CY1117964T1 CY 1117964 T1 CY1117964 T1 CY 1117964T1 CY 20161100858 T CY20161100858 T CY 20161100858T CY 161100858 T CY161100858 T CY 161100858T CY 1117964 T1 CY1117964 T1 CY 1117964T1
- Authority
- CY
- Cyprus
- Prior art keywords
- active substance
- composition
- psychological
- administration
- long
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Η παρούσα εφεύρεση αφορά μια σύνθεση, η οποία μπορεί να χρησιμοποιηθεί για την χορήγηση μιας αντιψυχωσικής δραστικής ουσίας, όπως ρισπεριδόνη υπό την μορφή ενός ενέσιμου, επί τόπου σχηματιζόμενου βιοαποικοδομήσιμου εμφυτεύματος για παρατεταμένη αποδέσμευση, το οποίο παρέχει θεραπευτικά επίπεδα στο πλάσμα από την πρώτη ημέρα. Η σύνθεση ευρίσκεται υπό την μορφή ενός εναιωρήματος δραστικής ουσίας σε ένα βιοαποικοδομήσιμο και βιοσυμβατό διάλυμα συμπολυμερούς ή συμπολυμερών με την χρήση αναμίξιμων με νερό διαλυτών, το οποίο χορηγείται σε υγρή μορφή. Μόλις η σύνθεση έλθει σε επαφή με τα σωματικά υγρά η πολυμερική μήτρα σκληραίνει συγκρατώντας την δραστική ουσία, σχηματίζοντας ένα στερεό ή ημιστερεό εμφύτευμα, το οποίο αποδεσμεύει την δραστική ουσία κατά έναν συνεχή τρόπο. Θεραπευτικά επίπεδα της δραστικής ουσίας στο πλάσμα μπορούν να επιτευχθούν από την πρώτη ημέρα έως επί τουλάχιστον 14 ημέρες ή περισσότερο.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382154.2A EP2394664B1 (en) | 2010-05-31 | 2010-05-31 | Antipsychotic injectable depot composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117964T1 true CY1117964T1 (el) | 2017-05-17 |
Family
ID=43301889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100857T CY1117969T1 (el) | 2010-05-31 | 2016-08-31 | Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης |
| CY20161100858T CY1117964T1 (el) | 2010-05-31 | 2016-08-31 | Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεας |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100857T CY1117969T1 (el) | 2010-05-31 | 2016-08-31 | Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US10085936B2 (el) |
| EP (2) | EP2394664B1 (el) |
| JP (1) | JP5882993B2 (el) |
| KR (1) | KR101784330B1 (el) |
| CN (1) | CN103002917B (el) |
| AP (1) | AP3524A (el) |
| AU (1) | AU2011260318B2 (el) |
| BR (1) | BR112012030686B1 (el) |
| CA (1) | CA2800111C (el) |
| CL (1) | CL2012003350A1 (el) |
| CY (2) | CY1117969T1 (el) |
| DK (2) | DK2394664T3 (el) |
| EA (1) | EA024155B1 (el) |
| ES (2) | ES2589106T3 (el) |
| HR (2) | HRP20161049T1 (el) |
| HU (2) | HUE029895T2 (el) |
| IL (1) | IL223129A (el) |
| LT (2) | LT2394664T (el) |
| MA (1) | MA34296B1 (el) |
| ME (1) | ME02501B (el) |
| MX (1) | MX338373B (el) |
| MY (1) | MY161930A (el) |
| NZ (1) | NZ604342A (el) |
| PL (2) | PL2394664T3 (el) |
| PT (2) | PT2394664T (el) |
| RS (1) | RS55190B1 (el) |
| SG (1) | SG185775A1 (el) |
| SI (2) | SI2394664T1 (el) |
| SM (2) | SMT201600320B (el) |
| UA (1) | UA108885C2 (el) |
| WO (1) | WO2011151355A1 (el) |
| ZA (1) | ZA201209346B (el) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| CN101801415B (zh) | 2007-05-25 | 2015-09-23 | Rb医药品有限公司 | 利培酮化合物的持续递送制剂 |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| HUE029895T2 (en) | 2010-05-31 | 2017-04-28 | Farm Rovi Lab Sa | Antipsychotic injectable depot preparation |
| HUE057236T2 (hu) | 2010-05-31 | 2022-04-28 | Farm Rovi Lab Sa | Készítmények befecskendezhetõ in-situ biológiailag lebontható implantátumokhoz |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| DK2529756T3 (da) | 2011-05-31 | 2021-08-02 | Farm Rovi Lab Sa | Risperidon- og/eller paliperidon-implantatformulering |
| ES2456917T3 (es) * | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| EP2986278A1 (en) | 2013-03-11 | 2016-02-24 | DURECT Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
| WO2016199170A2 (en) * | 2015-06-10 | 2016-12-15 | Cipla Limited | Paliperidone palmitate particles and compositions thereof |
| AU2018238136A1 (en) | 2017-03-20 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
| CN109589304A (zh) * | 2017-10-01 | 2019-04-09 | 万特制药(海南)有限公司 | 利培酮口服溶液及其制备方法 |
| CN110420212A (zh) * | 2019-08-19 | 2019-11-08 | 韩自勤 | 一种用于治疗精神分裂症组合物及其制备方法 |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| BE758156R (fr) | 1970-05-13 | 1971-04-28 | Ethicon Inc | Element de suture absorbable et sa |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4523591A (en) | 1982-10-22 | 1985-06-18 | Kaplan Donald S | Polymers for injection molding of absorbable surgical devices |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5620700A (en) | 1990-10-30 | 1997-04-15 | Alza Corporation | Injectable drug delivery system and method |
| US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| DK0729357T3 (da) | 1993-11-19 | 2005-06-06 | Janssen Pharmaceutica Nv | Mikroindkapslede 1,2-benzazoler |
| ES2158611T3 (es) | 1996-12-20 | 2001-09-01 | Alza Corp | Composicion en gel inyectable con efecto retard y procedimiento para la preparacion de dicha composicion. |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6331317B1 (en) * | 1999-11-12 | 2001-12-18 | Alkermes Controlled Therapeutics Ii Inc. | Apparatus and method for preparing microparticles |
| EP1248596B1 (de) * | 2000-01-11 | 2007-03-07 | Roland Bodmeier | Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel |
| US6604561B2 (en) * | 2000-02-11 | 2003-08-12 | Medical Instill Technologies, Inc. | Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial |
| DK1539101T3 (da) * | 2002-07-31 | 2009-04-27 | Alza Corp | Injicerbare, multi-modale polymere depotsammens tninger og anvendelser deraf |
| WO2004064752A2 (en) * | 2003-01-22 | 2004-08-05 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| US20050003007A1 (en) | 2003-07-02 | 2005-01-06 | Michele Boix | Method of sterilization of polymeric microparticles |
| JP2008518881A (ja) * | 2003-07-18 | 2008-06-05 | オークウッド ラボラトリーズ，エル．エル．シー． | 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止 |
| US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| DE102005031868A1 (de) * | 2005-07-04 | 2007-01-18 | Biotronik Vi Patent Ag | Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung |
| US8852638B2 (en) * | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US8076448B2 (en) | 2006-10-11 | 2011-12-13 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
| FR2908775B1 (fr) * | 2006-11-17 | 2012-08-31 | Biomatlante | Hydrogel et ses applications biomedicales |
| ES2755374T3 (es) | 2007-02-15 | 2020-04-22 | Tolmar Therapeutics Inc | Poli(lactida/glicolida) de descarga lenta y métodos para producir polímeros |
| EP2167039B1 (en) * | 2007-05-18 | 2016-09-28 | Durect Corporation | Improved depot formulations |
| CN101801415B (zh) * | 2007-05-25 | 2015-09-23 | Rb医药品有限公司 | 利培酮化合物的持续递送制剂 |
| CL2008003305A1 (es) * | 2007-11-06 | 2009-06-05 | M/S Panacea Biotec Ltd | Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer. |
| WO2010018159A1 (en) * | 2008-08-12 | 2010-02-18 | Novartis Ag | Pharmaceutical compositions |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| HUE057236T2 (hu) | 2010-05-31 | 2022-04-28 | Farm Rovi Lab Sa | Készítmények befecskendezhetõ in-situ biológiailag lebontható implantátumokhoz |
| HUE029895T2 (en) | 2010-05-31 | 2017-04-28 | Farm Rovi Lab Sa | Antipsychotic injectable depot preparation |
| ES2456917T3 (es) | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
| DK2529756T3 (da) | 2011-05-31 | 2021-08-02 | Farm Rovi Lab Sa | Risperidon- og/eller paliperidon-implantatformulering |
-
2010
- 2010-05-31 HU HUE10382154A patent/HUE029895T2/en unknown
- 2010-05-31 EP EP10382154.2A patent/EP2394664B1/en active Active
- 2010-05-31 LT LTEP10382154.2T patent/LT2394664T/lt unknown
- 2010-05-31 SI SI201031270A patent/SI2394664T1/sl unknown
- 2010-05-31 PT PT103821542T patent/PT2394664T/pt unknown
- 2010-05-31 ES ES10382154.2T patent/ES2589106T3/es active Active
- 2010-05-31 PL PL10382154.2T patent/PL2394664T3/pl unknown
- 2010-05-31 DK DK10382154.2T patent/DK2394664T3/en active
-
2011
- 2011-05-31 BR BR112012030686-3A patent/BR112012030686B1/pt active IP Right Grant
- 2011-05-31 KR KR1020127033021A patent/KR101784330B1/ko active IP Right Grant
- 2011-05-31 SG SG2012087136A patent/SG185775A1/en unknown
- 2011-05-31 WO PCT/EP2011/059000 patent/WO2011151355A1/en active Application Filing
- 2011-05-31 ES ES11725383.1T patent/ES2592527T3/es active Active
- 2011-05-31 AU AU2011260318A patent/AU2011260318B2/en active Active
- 2011-05-31 PL PL11725383.1T patent/PL2575890T3/pl unknown
- 2011-05-31 MX MX2012013937A patent/MX338373B/es active IP Right Grant
- 2011-05-31 JP JP2013512879A patent/JP5882993B2/ja active Active
- 2011-05-31 PT PT117253831T patent/PT2575890T/pt unknown
- 2011-05-31 MA MA35428A patent/MA34296B1/fr unknown
- 2011-05-31 RS RS20160730A patent/RS55190B1/sr unknown
- 2011-05-31 ME MEP-2016-178A patent/ME02501B/me unknown
- 2011-05-31 UA UAA201214486A patent/UA108885C2/ru unknown
- 2011-05-31 CA CA2800111A patent/CA2800111C/en active Active
- 2011-05-31 EP EP11725383.1A patent/EP2575890B1/en active Active
- 2011-05-31 DK DK11725383.1T patent/DK2575890T3/en active
- 2011-05-31 EA EA201201569A patent/EA024155B1/ru unknown
- 2011-05-31 NZ NZ604342A patent/NZ604342A/en unknown
- 2011-05-31 SI SI201130939A patent/SI2575890T1/sl unknown
- 2011-05-31 CN CN201180026475.2A patent/CN103002917B/zh active Active
- 2011-05-31 MY MYPI2012701044A patent/MY161930A/en unknown
- 2011-05-31 AP AP2012006626A patent/AP3524A/xx active
- 2011-05-31 HU HUE11725383A patent/HUE029056T2/en unknown
- 2011-05-31 LT LTEP11725383.1T patent/LT2575890T/lt unknown
-
2012
- 2012-11-19 IL IL223129A patent/IL223129A/en active IP Right Grant
- 2012-11-29 CL CL2012003350A patent/CL2012003350A1/es unknown
- 2012-11-30 US US13/690,647 patent/US10085936B2/en active Active
- 2012-12-10 ZA ZA2012/09346A patent/ZA201209346B/en unknown
-
2016
- 2016-08-19 HR HRP20161049TT patent/HRP20161049T1/hr unknown
- 2016-08-29 HR HRP20161100TT patent/HRP20161100T1/hr unknown
- 2016-08-31 CY CY20161100857T patent/CY1117969T1/el unknown
- 2016-08-31 CY CY20161100858T patent/CY1117964T1/el unknown
- 2016-09-15 SM SM201600320T patent/SMT201600320B/it unknown
- 2016-09-15 SM SM201600321T patent/SMT201600321B/it unknown
-
2018
- 2018-04-04 US US15/944,894 patent/US10182982B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117964T1 (el) | Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεας | |
| CY1120878T1 (el) | Ενδομητριο συστημα χορηγησης για αντισυλληψη | |
| CY1114975T1 (el) | Σκευασμα εμφυτευματος παλιπεριδονης | |
| EA201400172A1 (ru) | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства | |
| BRPI0516830A (pt) | composições de droga de liberação sustentada convenientemente implantáveis | |
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| NI201200113A (es) | Derivados de 3 - hidroxi - 5 - arilisotiazol novedosos | |
| AR064078A1 (es) | Sistema de administracion de farmacos intraocular inyectable biocompatible, su uso para preparar un medicamento y proceso para su preparacion | |
| CY1123398T1 (el) | Συνθεση συνδυασμου | |
| ECSP14023048A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| CO6251360A2 (es) | Bromhidrato de bupropion y aplicaciones terapeuticas | |
| PA8815901A1 (es) | Sistema de administracion de drogas con efecto estabilizante | |
| DOP2014000003A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| CL2022000729A1 (es) | Derivado de heteroarilamidopiridinol y composición farmacéutica que comprende el mismo como ingrediente activo para prevención o tratamiento de enfermedad autoinmune | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| ECSP11011199A (es) | Formulación de depósito de octreotida con niveles de exposición constantemente altos | |
| UA109544C2 (uk) | Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення | |
| AR099680A1 (es) | Muteínas mejoradas de factor viii de coagulación | |
| BR112018007399A2 (pt) | composição, método de tratamento, kit de partes e forma de dosagem | |
| NZ604009A (en) | A combination composition comprising ibuprofen and paracetamol | |
| ECSP17081071A (es) | Composiciones de matriz polimérica tópicas que comprenden una alta concentración de hialuronato de sodio bio-fermentado y sus usos | |
| EA202092021A1 (ru) | Инъекционная композиция | |
| BR112021026025A2 (pt) | Polímeros biodegradáveis ultrassensíveis ao ph | |
| RU2007141393A (ru) | Способ лечения спастического и болевого синдромов у пациентов с последствиями позвоночно-спинномозговой травмы | |
| AR097635A1 (es) | Formulación de liberación sostenida de mosapride que proporciona efectos farmacológicos y clínicos con administración una vez por día |